Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;11(12):396-403.
doi: 10.5489/cuaj.4486. Epub 2017 Nov 1.

Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices

Affiliations

Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices

Mitchell Geoffrey Goldenberg et al. Can Urol Assoc J. 2017 Dec.

Abstract

Introduction: In 2014, the Canadian Task Force on Preventive Health Care (CTFPHC) recommended against routine prostate cancer screening with the prostate-specific antigen (PSA) blood test. We surveyed Canadian primary care physicians (PCPs) to understand their opinions and attitudes towards prostate cancer screening in 2016.

Methods: Twenty PCPs piloted the survey to assess its accessibility. We distributed a flyer to 19 633 PCPs as an insert in a large mailed package inviting them to attend a national meeting, and later promoted the survey at the meeting. Multinomial logistic regression models examined factors associated with agreement of key guideline statements and the overall benefit of PSA screening.

Results: A total of 1254 PCPs responded (rate of 6.4%); 54.7% of physicians aware of the CTFPHC recommendations report screening less often as a result. Overall, 55.6% of PCPs feel that the risks of PSA screening outweigh the benefits. On multivariable analysis, physicians who did not read the guidelines, did not have an academic appointment, or were in practice for over 20 years were significantly more likely to disagree with the statement that men 55-69 years old should not be screened for prostate cancer with PSA.

Conclusions: Our national survey found that the prostate cancer screening practices of Canadian PCPs varies widely across physician demographic groups, with almost equal numbers for or against. This has significant ethical, medical, and legal implications. The poor response rate to highly incentivized survey request may suggest a reluctance or general apathy towards this subject because of the Task Force recommendations. Future efforts should provide physicians with objective guidance around PSA screening, incorporating input from all stakeholders, including PCPs, urologists, and patients.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Greenberg is an advisor for J&J and has received payment from AstraZeneca. The remaining authors report no competing personal or financial interests.

Figures

Fig. 1
Fig. 1
Respondent agreement with routine screening in men of different age groups. PSA: prostate-specific antigen.
Fig. 2
Fig. 2
Screening practices in men with different risk profiles.
Fig. 3
Fig. 3
At what ago do you start/stop offering routine cancer screening in average-risk men?
Fig. 4
Fig. 4
Respondents’ agreement with a shared-decision approach to screening.
Fig. 5
Fig. 5
Counselling patients on risks of prostate-specific antigen screening.

Similar articles

Cited by

References

    1. Statistics CCSACOC. Canadian Cancer Statistics 2015. Toronto, ON: Canadian Cancer Society; 2015.
    1. Bunting PS, Goel V, Williams JI, et al. Prostate-specific antigen testing in Ontario: Reasons for testing patients without diagnosed prostate cancer. CMAJ. 1999;160:70–5. - PMC - PubMed
    1. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–34. doi: 10.7326/0003-4819-157-2-201207170-00459. - DOI - PubMed
    1. Krahn M. Prostate cancer screening: Going beyond the clinical evidence. CMAJ. 2014;186:1201. doi: 10.1503/cmaj.141252. - DOI - PMC - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–8. doi: 10.1056/NEJMoa0810084. - DOI - PubMed
-